Published
October 2, 2026
Former Revance Therapeutics stockholders who were cashed out at $3.65 a share when Crown Laboratories closed its acquisition on February 6, 2025, and whose shares are not compensated in the separate Revance securities settlement, may qualify to claim a pro rata payment from the $2.4 million Revance stockholder class action settlement. Claims close March 17, 2027; the settlement hearing is set for December 17, 2026.
Current Status
Claims are open. A Proof of Claim must be submitted online or postmarked by March 17, 2027. The Delaware Court of Chancery entered a scheduling order on September 14, 2026 directing notice to the class, and the settlement hearing is set for December 17, 2026, at 11:00 a.m. The settlement has not received final approval, and no payment date has been announced as of October 2, 2026. Only class members who file a claim are paid.Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Status
Claims Open
Claim Deadline
March 17, 2027
Online or postmarked · objections due December 3, 2026 · no opt-out
Estimated Payout
Pro Rata Share of $2.4M
Based on eligible shares · no per-share estimate published · no payment under $10
Proof Required
Yes — Brokerage Records
Documented holdings as of February 29, 2024 and every later purchase through February 6, 2025
What Changed Recently?
Mark J. Foley, a former director and officer of Revance Therapeutics, agreed to pay $2.4 million to settle two consolidated stockholder class actions in the Delaware Court of Chancery, Gilmore v. Foley and Jones v. Foley. The parties signed the settlement stipulation on August 7, 2026, and the court entered a scheduling order on September 14, 2026.According to the notice, Crown Laboratories first agreed in August 2024 to buy Revance for $6.66 a share. Days later, Revance’s distribution partner Teoxane SA claimed Revance had breached their distribution agreement, and after that dispute the deal was renegotiated to $3.65 a share, closing on February 6, 2025. The plaintiffs allege that Foley breached his fiduciary duties by mismanaging the Teoxane relationship in a way that let Crown reprice the deal, by putting his own liquidity and severance payments ahead of stockholders, and by issuing misleading disclosures about the tender offer. Foley denies all of these allegations, maintains that the merger was fair and the disclosures accurate, and agreed to settle without admitting wrongdoing. The court has made no findings on the merits.
Who Qualifies?
The class includes former record and beneficial holders of Revance common stock as of the February 6, 2025 merger closing who received $3.65 a share in cash and who acquired those shares either before February 29, 2024, or between February 29, 2024 and February 6, 2025 but are not eligible for compensation on those shares in the federal securities settlement, In re Revance Therapeutics, Inc. Securities Litigation, No. 3:25-cv-0018 (M.D. Tenn.).In practice, shares bought before February 29, 2024 and held through the closing are the core of this class, while shares bought during the federal class period are generally covered by the federal settlement instead. Foley, Crown, officers and directors of Revance or Crown at the closing, their immediate families, and accounts held for their benefit are excluded.
How Much Can You Get?
Payments are pro rata by eligible shares, measured against the total eligible shares of everyone who files a valid claim. The notice does not give a per-share estimate. It notes that not every eligible holder files, which usually raises the amount for those who do. No payment is made to anyone whose share would be less than $10.The net settlement fund is the $2.4 million plus interest, minus taxes, notice and administration costs, and any fee award. Plaintiffs’ counsel will ask for up to 28% of the fund, including up to $25,000 in expenses, with incentive awards of up to $5,000 for each plaintiff paid out of that fee award.
What Proof or Notice ID Is Required?
No notice ID is needed, but holdings must be documented. The Proof of Claim asks for the number of Revance shares held at the opening of trading on February 29, 2024, and a list of every purchase from then through February 6, 2025 with dates, share counts and prices; both sections are marked as requiring documentation. Broker confirmations, trade confirmations or account screenshots are accepted. The form also asks whether the claimant filed a claim or received payment in the federal securities settlement and, if so, for a copy of that claim.What Is the Deadline?
Proofs of Claim must be submitted online or postmarked by March 17, 2027. One line of the printable claim form reads March 17, 2017, which appears to be a typo; the notice, the rest of the form and the settlement website all give 2027.Class members cannot opt out. Objections to the settlement, the plan of allocation or the fee request, and requests to speak at the hearing, must be received by the court or postmarked by December 3, 2026, following the instructions in the notice.
How Do You Take Action?
File online through the claims portal linked from the official Revance settlement page run by RG/2 Claims Administration, or download the Proof of Claim there and mail it. Gather brokerage statements covering February 29, 2024 through February 6, 2025 before starting, since the form asks for both the starting position and every purchase in between.A separate Delaware buyout settlement for National Holdings stockholders is also open, and other investor cases are listed on the securities class actions hub.
What Happens Next?
The court will hold the settlement hearing on December 17, 2026, at 11:00 a.m. at the Leonard L. Williams Justice Center in Wilmington, or by Zoom at the court’s discretion, to decide whether to approve the settlement, the plan of allocation and the fee request. Payments will be distributed only after approval and after the time for any appeal has run. No payment date had been announced as of October 2, 2026.Sources and Verification
- Revance settlement — official RG/2 Claims Administration page
- Notice of Pendency of Stockholder Class Actions and Proposed Settlement
- Proof of Claim and Release, Gilmore v. Foley, C.A. No. 2025-1415-NAC, and Jones v. Foley, C.A. No. 2026-0177-NAC, Delaware Court of Chancery
Questions
How is this different from the Revance securities settlement?
The federal securities case in Tennessee covers people who bought Revance securities between February 29, 2024 and February 6, 2025. This Delaware settlement covers stockholders cashed out in the merger, mainly those whose shares were bought before February 29, 2024, plus any later-bought shares that are not eligible for compensation in the federal settlement. Shares compensated in the federal settlement are excluded here.
Can I opt out?
No. The court certified the class as a non-opt-out class under Delaware Court of Chancery Rules 23(b)(1) and 23(b)(2). Class members who disagree with the settlement can object by December 3, 2026.
Is there a minimum payment?
Yes. No payment is made to a claimant whose share would be less than $10.
The claim form says March 17, 2017. Which deadline is right?
One line of the printable claim form reads March 17, 2017, which appears to be a typo. The court-authorized notice, the rest of the claim form and the settlement website all give March 17, 2027.
Official Settlement Notice
For more class actions keep scrolling below.
Settlement Amount
$2,400,000
Case Title
Gilmore v. Foley; Jones v. Foley
Case Number
C.A. Nos. 2025-1415-NAC and 2026-0177-NAC
Court
Court of Chancery of the State of Delaware
Final Approval Hearing
December 17, 2026 at 11:00 AM
Leonard L. Williams Justice Center, Wilmington, or by Zoom
Administrator
RG/2 Claims Administration LLC
Official Website
RG2 Claims — Revance
